The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|October 31, 2017
Dr. Geynisman on Patient Preferences for Treatment of RCC
Author(s)Daniel M. Geynisman, MD
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).
Advertisement
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).
According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.
Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.
Advertisement
Related to this article
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5